FC2ブログ

バイオの戯言

ライフサイエンスに関する話題についてコメント(戯言?)を述べていくブログです。

【プレスリリースメモ】 RNAi関係 (2013.1.12)  

<Alnylam Pharmaceuticals>
Alnylam to Webcast Presentation at 31st Annual J.P. Morgan Healthcare Conference(2013.1.2)
Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)(2013.1.3)
Alnylam Provides Key 2013 – 2014 Goals for RNAi Therapeutics Pipeline(2013.1.6)

<Mesoblast>(Angioblast Systemsを買収)
MESOBLAST’S NEOFUSE STEM CELL PRODUCT SHOWS POSITIVE RESULTS IN PHASE 2 LUMBAR SPINAL FUSION TRIAL Results support progression of clinical development to Phase 3(2013.1.11)

<Asuragen>
Rolland Carlson, Ph.D. named CEO of Asuragen(2013.1.7)

<Aura Biosciences>
Former Genzyme Prez Joins $3.2M Round for Aura Biosciences(2012.12.27)

<Benitec>
Presentation at Cowen US Investor Showcase(2013.1.8)
Corporate Presentation at Cappello US Investor Conference(2013.1.8)
Benitec Presents at US-Based Investor Conferences(2013.1.8)

<Bio-Path Holdings>
Bio-Path Holdings to Present at Biotech Showcase 2013 on Tuesday, January 8, 2013 at 11:00 am Pacific Time - Webcast Link(2012.12.31)
Bio-Path Holdings to Present at Biotech Showcase 2013 on Tuesday, January 8, 2013 at 11:00 am Pacific Time(2013.1.3)
Slides from Biotech Showcase 2013 Presentation(2013.1.9)

<Cerulean Pharma>
Cerulean Announces First Patient Dosed in Phase 2 Pharmacodynamic Study of CRLX101 in Gastric Cancer(2013.1.3)
CRLX101 Advances to Second Stage of Phase 2 Clinical Trial in Advanced Ovarian Cancer(2013.1.7)

<CytRx Corporation>
CytRx to Present at the Biotech Showcase 2013 Conference(2013.1.2)
CytRx Promotes Dr. Daniel Levitt to Executive Vice President(2013.1.3)

<Devgen>
Devgen receives several shareholder notifications(2013.1.4)

<Dicerna Pharmaceuticals>
Dicerna Announces that Kyowa Hakko Kirin has Selected a Second DsiRNA Therapeutic Candidate for Development, Triggering $5 Million Milestone Payment(2013.1.3)

<Generex Biotechnology>
Generex Announces Investor Conference Call(2013.1.11)

<Gene Signal>
・Gene Signal presents at Canada House reception during Genesis 2012 conference in London; ties in runner up position for best presentation(2012.12.12)
・Gene Signal attends 2013 JP Morgan Conference in St Francisco, USA(2013.1.7)

<Gradalis>
Gradalis, Inc. Closes $24 Million in Series B Financing to Advance Late-Stage Trials of FANG™ Personalized Cancer Vaccine(2013.1.3)

<iCo Therapeutics>
iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update(2013.1.3)

<Isis Pharmaceuticals>
Isis Pharmaceuticals To Present At The 31st Annual J.P. Morgan Healthcare Conference(2013.1.2)
Isis Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference(2013.1.7)

<Lorus Therapeutics>
Lorus Therapeutics Announces Successful Dose Escalation of its Phase I Clinical Trial of LOR-253 and Initiation of a Biomarker Clinical Study in Cancer Patients(2013.1.7)

<miRagen Therapeutics>
Santaris Pharma A/S and miRagen Therapeutics Inc. Expand Worldwide Strategic Alliance to Discover and Develop LNA-drugs Against Disease-Causing microRNAs(2013.1.8)

<OPKO Health>
OPKO Health to Present at the 31st Annual J.P. Morgan Healthcare Conference(2013.1.4)
OPKO Health to Acquire Two Phase 3 Products(2013.1.8)

<Prosensa>
Prosensa to Present at J.P. Morgan Healthcare Conference(2013.1.3)

<Regulus Therapeutics>
Regulus to Present at 31st Annual J.P. Morgan Healthcare Conference(2013.1.3)

<Rosetta Genomics>
Rosetta Genomics to Present at Sidoti & Company 2013 Micro-Cap Conference(2013.1.4)
Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors Published in Clinical Experimental Metastasis(2013.1.9)

<RXi Pharmaceuticals>
RXi Pharmaceuticals to Webcast Presentation at Biotech Showcase™ 2013(2013.1.3)

<Santaris Pharma>
USPTO Grants Santaris' Request for Inter-Partes Reexamination of Patent licensed to Regulus(2013.1.7)
Santaris Pharma A/S and miRagen Therapeutics Inc. expand worldwide strategic alliance to discover and develop LNA-drugs against disease causing microRNAs(2013.1.8)

<Silence Therapeutics>
Total Voting Rights(2012.12.31)
Appointment of Chief Medical Officer(2013.1.2)

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals To Present At 31st Annual J.P. Morgan Healthcare Conference(2013.1.2)
Valeant Pharmaceuticals Announces New Management Appointment(2013.1.3)

<Vical>
Vical Named to NASDAQ Global Select Market(2013.1.2)
Vical to Present at 31st Annual J.P. Morgan Healthcare Conference(2013.1.3)

<アンジェスMG>
行使価額修正条項付新株予約権の月間行使状況に関するお知らせ(2013.1.4)
経営合理化策の実施について(2013.1.9)

<ボナック>
第35回日本分子生物学会年会バイオテクノロジーセミナー「進化するRNAiテクノロジー」(2012.12.26)


スポンサーサイト
[ 2013/01/12 15:33 ] プレスリリース | TB(0) | CM(0)
コメントの投稿













管理者にだけ表示を許可する
最新ニュース
お気に入り
カレンダー(月別)
07 ≪│2018/08│≫ 09
- - - 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 -
特選品
特許関係の書籍-3
特許関係の書籍-2
特許関係の書籍-1
情報関係の書籍
月別アーカイブ
プロフィール

のぐひで

Author:のぐひで
FC2ブログへようこそ!